India Awaits the UK's COVID-19 Vaccine Authorization

London-based AstraZeneca's CEO Pascal Soriot told the TheTimes on December 27, 2020, the experimental COVID-19 vaccine candidate AZD1222 has achieved a “winning formula” efficacy. Soriot stated the University of Oxford developed vaccine can provide ‘100 protection’ against severe COVID-19 after initially showing an average of 70% effectiveness. And he indicated the UK may complete the review process by the end of December 2020.

This news supports India's vaccine regulators' efforts to approve this COVID-19 vaccine for emergency use.

BusinessToday reported Serum Institute of India (SII) has already manufactured 40 million doses of the ''Covishield' vaccine candidate. SII confirmed last week it had submitted additional data required by the Drug Controller General of India to expedite the authorization process.